Limits...
Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.

Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima A, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y - Cancer Sci. (2014)

Bottom Line: High levels of c-MET expression (c-MET-high) in the primary tumors were observed in 52% of patients.Relapse-free survival was significantly shorter for patients with c-MET-high primary tumors (9.7 months) than for those with c-MET-low primary tumors (21.1 months) (P = 0.013).These results suggest that a high level of genetic concordance in KRAS, BRAF and PIK3CA between primary tumors and liver metastases, and c-MET-high in the primary tumors were associated with shorter relapse-free survival after hepatic metastasectomy.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Show MeSH

Related in: MedlinePlus

Relapse-free survival curve calculated using the Kaplan–Meier method for groups classified according to the c-MET expression level in primary tumors.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317860&req=5

fig02: Relapse-free survival curve calculated using the Kaplan–Meier method for groups classified according to the c-MET expression level in primary tumors.

Mentions: The median RFS among patients with c-MET-high primary tumors (9.7 months) was significantly shorter than the median RFS among those with c-MET-low primary tumors (21.1 months) (P = 0.013; Fig. 2). However, the median RFS among patients with c-MET-high expression in liver metastases (9.1 months) was not significantly shorter than the median RFS among those with c-MET-low liver metastases (14.5 months) (P = 0.147; Fig. 3).


Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.

Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima A, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y - Cancer Sci. (2014)

Relapse-free survival curve calculated using the Kaplan–Meier method for groups classified according to the c-MET expression level in primary tumors.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317860&req=5

fig02: Relapse-free survival curve calculated using the Kaplan–Meier method for groups classified according to the c-MET expression level in primary tumors.
Mentions: The median RFS among patients with c-MET-high primary tumors (9.7 months) was significantly shorter than the median RFS among those with c-MET-low primary tumors (21.1 months) (P = 0.013; Fig. 2). However, the median RFS among patients with c-MET-high expression in liver metastases (9.1 months) was not significantly shorter than the median RFS among those with c-MET-low liver metastases (14.5 months) (P = 0.147; Fig. 3).

Bottom Line: High levels of c-MET expression (c-MET-high) in the primary tumors were observed in 52% of patients.Relapse-free survival was significantly shorter for patients with c-MET-high primary tumors (9.7 months) than for those with c-MET-low primary tumors (21.1 months) (P = 0.013).These results suggest that a high level of genetic concordance in KRAS, BRAF and PIK3CA between primary tumors and liver metastases, and c-MET-high in the primary tumors were associated with shorter relapse-free survival after hepatic metastasectomy.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Show MeSH
Related in: MedlinePlus